Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Paradigms
100%
Chronic Myeloid Leukemia
100%
Second-generation Tyrosine Kinase Inhibitors
100%
Third-generation Tyrosine Kinase Inhibitor
100%
Tyrosine Kinase Inhibitor
50%
Prognostic Factors
33%
Dasatinib
33%
Ponatinib
33%
Nilotinib
33%
Subsequent Therapy
33%
Treatment Lines
33%
Tolerability
16%
Clinical Practice Guidelines
16%
Chronic Phase
16%
First-line Therapy
16%
Long-term Benefit
16%
Limited Value
16%
Leukemia Patients
16%
Event-free Survival
16%
Investigational Agents
16%
Salvage Therapy
16%
Intolerance
16%
Imatinib
16%
Imatinib Resistance
16%
Cytogenetic Response
16%
Intercurrent Events
16%
Mutation Status
16%
Guide Selection
16%
Bosutinib
16%
Tyrosine Kinase Inhibitor Therapy
16%
BCR-ABL mutations
16%
Imatinib Intolerance
16%
EGFR-TKI Resistance
16%
Third-line Therapy
16%
Generation Agent
16%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Chronic Myelogenous Leukemia
100%
Prognostic Factor
18%
Dasatinib
18%
Ponatinib
18%
Nilotinib
18%
Myeloid Leukemia
9%
Event Free Survival
9%
Salvage Therapy
9%
Imatinib
9%
Clinical Guideline
9%
Bosutinib
9%
Imatinib Resistance
9%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Chronic Myeloid Leukemia
100%
Dasatinib
18%
Ponatinib
18%
Nilotinib
18%
Imatinib
18%
Tolerability
9%
Myeloid Leukemia
9%
Event Free Survival
9%
Bosutinib
9%
Investigational Agent
9%